Preparation And Characterization Of Mangiferin Encapsulated Albumin Nanoparticles For The Treatment Of Inflammation

Abstract

The objective of the current investigation was to develop albumin nanoparticles loaded with mangiferin for prolonged release and improving half-life and bioavailability of manfigerin. The nanoparticles were prepared from bovine serum albumin using ethanol as the desolvating solvent and glutaraldehyde as the crosslinking agent. The optimization of pH, crosslinking time and volume of desolvating solvent was done to obtain lowest particles size, high entrapment efficiency. All the formulations were obtained in yield ranging from 73.5 to 88.7%. The particle size of the nanoparticles ranged from 167.3 to 267.1 nm. The zeta potential of all the formulations was negative and ranged from -29.1 to -31.5 meV. The high zeta potential helps in preventing the aggregation of the particles. The percent entrapment of mangiferin in the formulations ranged from 60.7 to 88.6%. F7 was selected as the best formulation (88.6% entrapment and 195.6 nm size) prepared using 50 mL desolvating solvent (ethanol), pH 8.0 and crosslinking time of 24 hours. Mangiferin was released from the standard solution in 4 hours (100.6%). On the other hand 98.2% mangiferin was released from the albumin nanoparticles F7 in 24 hours. The mangiferin loaded albumin nanoparticles exhibited the inhibition of albumin denaturation comparable to pure mangiferin. The albumin nanoparticle formulation F7 had shown the inhibition capacity (84.63 ± 0.249%). The inhibition protein denaturation by 100 µg/mL solution of standard drug mangiferin was found to be 87.60 ± 0.509%.